Base de dados : MEDLINE
Pesquisa : C11.675.349.500 [Categoria DeCS]
Referências encontradas : 13528 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1353 ir para página                         

  1 / 13528 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29177260
[Au] Autor:Tay WL; Tong AKT; Hui KYD; Tang YLC; Chng CL
[Ad] Endereço:Department of Endocrinology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore. weilin.tay@mohh.com.sg.
[Ti] Título:Radioiodine associated de novo Graves' opthalmopathy in an Asian cohort.
[So] Source:Hell J Nucl Med;20(3):227-231, 2017 Sep-Dec.
[Is] ISSN:1790-5427
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Radioactive iodine in the treatment of Graves' disease has been associated with the development of de novo Graves' ophthalmopathy (GO). In this report, we describe five individuals who required extensive ophthalmic treatment for post-RAI de novo GO.
[Mh] Termos MeSH primário: Doença de Graves/radioterapia
Oftalmopatia de Graves/dietoterapia
Oftalmopatia de Graves/etiologia
Radioisótopos do Iodo/efeitos adversos
Radioisótopos do Iodo/uso terapêutico
Lesões por Radiação/diagnóstico por imagem
Lesões por Radiação/etiologia
[Mh] Termos MeSH secundário: Adulto
Diagnóstico Diferencial
Feminino
Doença de Graves/diagnóstico por imagem
Seres Humanos
Masculino
Meia-Idade
Lesões por Radiação/prevenção & controle
Compostos Radiofarmacêuticos/efeitos adversos
Compostos Radiofarmacêuticos/uso terapêutico
Singapura
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Iodine Radioisotopes); 0 (Radiopharmaceuticals)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1967/s002449910606


  2 / 13528 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29177256
[Au] Autor:Chen Y; Huang J; Wang Y; Xie S; He F
[Ad] Endereço:Nuclear medicine department of Quanzhou, East Road 248#, Licheng District, Quanzhou City, China, 362000. 1526797743@qq.com.
[Ti] Título:Errors in the absorbed and the administered I therapeutic dose in patients with Graves' disease. A suggested more precise technique.
[So] Source:Hell J Nucl Med;20(3):217-221, 2017 Sep-Dec.
[Is] ISSN:1790-5427
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to evaluate the relative error (RE) in the thyroid absorbed dose (TD) of iodine-131 ( I) in patients with Graves' disease comparing the simplified Quimby-Marinelli-Hine formula method (sQMHF) and the Standard Operational Procedures for dosimetry (SOPD) recommended by the European Association of Nuclear Medicine. PATIENTS AND METHODS: This study included 45 patients with Graves' disease 12 men and 33 women; age 44.1±12.8 years. Thyroid mass (TM) was measured using ultrasound. Uptake of I (RAIU) was tested at 2, 4-6, 24, 48-72, and 96-168h after its administration and the half-life (T ) and resident time (RT) of I were computed. According to the sQMHF, a prescribed TD of 75Gy required 3.7MBq/g of I, correction based on the RAIU and T . Subsequently, the therapeutic TD was computed according to the SOPD and the RE was recorded. The data were analyzed using t-tests. RESULTS: The TM, RAIU , therapeutic TD, and RE were 36.5±23.9g, 0.54±0.14, 89.4±9.4Gy, and -0.01±0.02, respectively. There was a significant difference (t-value 9.84, P<0.01) between the prescribed and therapeutic TD because the sQMHF ignores the absorbed dose deposited in the thyroid during the first 24h, which is included in the SOPD. In addition, the RE was significantly smaller than the variable coefficient (VC) of the therapeutic TD (t=-39.6, P<0.01). CONCLUSION: When the activity of I was calculated using the simplified Q-M-H formula, the therapeutic absorbed thyroid dose was significantly higher than what was expected for the prescribed dose. Precision of the individualized therapeutic absorbed dose could be improved by computing the activity of I using the standard operational procedures for dosimetry of the EANM.
[Mh] Termos MeSH primário: Absorção Fisico-Química
Esquema de Medicação
Doença de Graves/metabolismo
Doença de Graves/radioterapia
Radioisótopos do Iodo/administração & dosagem
Radioisótopos do Iodo/farmacocinética
Erros de Medicação/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Masculino
Taxa de Depuração Metabólica
Compostos Radiofarmacêuticos/administração & dosagem
Compostos Radiofarmacêuticos/farmacocinética
Dosagem Radioterapêutica
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Iodine Radioisotopes); 0 (Iodine-131); 0 (Radiopharmaceuticals)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1967/s002449910602


  3 / 13528 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390537
[Au] Autor:Xuan YY; Li TF; Zhang L; Liu SY
[Ad] Endereço:Department of Rheumatology and Immunology, First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, P.R. China.
[Ti] Título:ANCA positive relapsing polychondritis, Graves disease, and suspected moyamoya disease: A case report.
[So] Source:Medicine (Baltimore);96(51):e9378, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIOINALE: Relapsing polychondritis (RP) is a rare and heterogeneous disease complex of unknown origin which basically affects cartilaginous structures, 40% of which accompanied by rheumatic, hematologic, and endocrine disease. Among them, vasculitis is the most common accompanying type and usually presented with positive antineutrophilic cytoplasmic antibody (ANCA). The presence of ANCA could be primary or drug-induced like propylthiouracil (PTU). Central involvement of RP is very rare, and there is almost no report of cerebral vasculopathy manifested as moyamoya. PATIENT CONCERNS: A 26-year-old woman complained about recurrent fever, auricular chondritis, ocular inflammation, and arthritis. She had an 8-year drug intake of PTU for Graves disease. Myeloperoxidase antineutrophilc cytoplasmic antibodies (MPO-ANCA) were found positive. Magnetic resonance angiography (MRA) detected multiple intracranial vasculopathy which we highly suspected it as moyamoya disease. DIAGNOSES: Relapsing polychondritis, Graves disease and suspected moyamoya disease were clinically diagnosed. INTERVENTIONS AND OUTCOMES: In case of possible PTU-induced vasculitis and the aggravation of vasculopathy, PTU was replaced by Iodine-131 (I) therapy. Induction treatment included oral prednisone 30 mg daily and oral cyclophosphamide 100 mg daily. Symptoms rapidly relieved before discharge. Inflammation markers were normal and MPO-ANCA decreased in 3 weeks after admission. Prednisone was gradually tapered to 7.5 mg daily and at month 10 azathioprine was continued for maintenance. LESSONS: RP can overlap with Graves disease and moyamoya disease; comprehensive tests should be performed when admission. When relapsing polychondritis is accompanied with Graves disease, especially when ANCA is positive, PTU should be avoided.
[Mh] Termos MeSH primário: Anticorpos Anticitoplasma de Neutrófilos/sangue
Doença de Graves/diagnóstico
Doença de Moyamoya/diagnóstico
Policondrite Recidivante/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Antitireóideos/uso terapêutico
Biomarcadores/sangue
Feminino
Doença de Graves/complicações
Doença de Graves/tratamento farmacológico
Seres Humanos
Doença de Moyamoya/complicações
Policondrite Recidivante/sangue
Policondrite Recidivante/complicações
Propiltiouracila/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Antithyroid Agents); 0 (Biomarkers); 721M9407IY (Propylthiouracil)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009378


  4 / 13528 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390469
[Au] Autor:Zeng XX; Tang YL; Hu KX; Wang J; Zhu LY; Liu JY; Xu J
[Ad] Endereço:Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
[Ti] Título:Insulin autoimmune syndrome in a pregnant female: A rare case report.
[So] Source:Medicine (Baltimore);96(51):e9213, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Insulin autoimmune syndrome (IAS) is an uncommon disorder characterized by hyperinsulinemic hypoglycemia related to insulin-binding autoantibodies. To the best of our knowledge, we report the first case of a pregnant female with IAS. PATIENT CONCERNS: The 26-year-old patient with Graves disease and 10 weeks pregnant developed IAS after approximately 6 months treatment with methimazole. The patient exhibited recurrent spontaneous hypoglycemia. DIAGNOSES: On evaluation, laboratory findings detected both high fasting insulin (>1000 mIU/L) and insulin autoantibodies. An oral glucose tolerance test showed elevated insulin concentrations with disproportionately elevated C-peptide levels. The imaging study showed nomasslesionsinthepancreas,and the patient was clinically diagnosed with IAS. INTERVENTIONS: The patient had an abortion, discontinued methimazole and switched to oral prednisone (30 mg once daily) and propylth- iouracil (100 mg 3 times daily) for 3 months. OUTCOMES: At the 3-month follow-up visit, hypoglycemic episodes had disappeared and insulin antibody levels were no longer detectable. LESSONS: We have described this case and reviewed the relevant literature concerning diagnosis and treatment of IAS. Importantly, this case indicates that clinicians should view pregnancy as another factor of hypoglycemia in IAS.
[Mh] Termos MeSH primário: Doenças Autoimunes/diagnóstico
Hipoglicemia/induzido quimicamente
Insulina/sangue
Metimazol/efeitos adversos
Complicações na Gravidez/diagnóstico
[Mh] Termos MeSH secundário: Aborto Espontâneo
Adulto
Feminino
Seguimentos
Idade Gestacional
Doença de Graves/diagnóstico
Doença de Graves/tratamento farmacológico
Seres Humanos
Hipoglicemia/imunologia
Hipoglicemia/fisiopatologia
Insulina/imunologia
Anticorpos Anti-Insulina/sangue
Metimazol/uso terapêutico
Prednisona/uso terapêutico
Gravidez
Doenças Raras
Medição de Risco
Síndrome
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Insulin); 0 (Insulin Antibodies); 554Z48XN5E (Methimazole); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009213


  5 / 13528 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29174716
[Au] Autor:Ramgopal S; Rathika C; Padma MR; Murali V; Arun K; Kamaludeen MN; Balakrishnan K
[Ad] Endereço:Department of Immunology, School of Biological Sciences, Madurai Kamaraj University, Madurai 625021, India.
[Ti] Título:Interaction of HLA-DRB1* alleles and CTLA4 (+49 AG) gene polymorphism in Autoimmune Thyroid Disease.
[So] Source:Gene;642:430-438, 2018 Feb 05.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Autoimmune Thyroid Diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), arise by the complex interaction of genes and environmental factors. The aim of present study was to study the susceptible associations of HLA-DRB1* alleles and CTLA4 +49 AG polymorphism in AITD in south India. AITD patients (n=235; HT=180; GD=55) and age/sex matched healthy controls (n, 235) were enrolled to type HLA-DRB1* alleles and 'CTLA4 +49 AG' by PCR-SSP and PCR-RFLP methods respectively. Analysis revealed CTLA4 +49 'GG' genotype was increased significantly in patients (PL: p=8.7×10 ; HT: p=9.3×10 ; GD: p=0.006). Decreased frequencies of 'AA' genotype was observed in patients (PL: p=9.4×10 ; HT: p=0.008; GD: p=9.0×10 ). Increased frequencies were observed for HLA alleles DRB1*12 (PL: p=1.42×10 ; HT: p=5.75×10 ; GD: p=0.002) and DRB1*11 (PL: p=0.0025; HT: p=0.013) in patients. Decreased frequencies for alleles DRB1*10 (PL: p=0.00002; HT: p=0.018; GD: p=1.63×10 ) and DRB1*03 (PL: p=0.003; HT: p=0.003) were observed, suggesting a protective association. Combinatorial/Synergistic analysis have revealed an increased frequencies for 'DRB1*11+AG' (PL: p=0.022), 'DRB1*12+AG' (PL: p=6.1×10 ; HT: p=0.0001), 'DRB1*04+GG' (PL: p=0.003; HT: p=0.008), 'DRB1*07+GG' (PL: p=0.009; HT: p=0.014) and 'DRB1*12+GG' (PL: p=0.005; HT: p=0.005) in patients. However, the combinations such as 'DRB1*10+AA' (PL: p=1.8×10 ; HT: p=0.003) and 'DRB1*15+AA' (PL: p=0.006; GD: p=0.011) were decreased in patients showing a protective association. The 'GG/G' of CTLA4 +49AG SNP, HLA-DRB1*11/-DRB1*12 (DR5) alleles and the combinations of DRB1*11/DRB1*12 alleles with AG/GG genotype and DRB1*04/07/12 alleles with GG genotype may act as synergistic manner to confer the strong susceptibility to AITD in south India.
[Mh] Termos MeSH primário: Antígeno CTLA-4/genética
Doença de Graves/genética
Cadeias HLA-DRB1/genética
Doença de Hashimoto/genética
Polimorfismo Genético
[Mh] Termos MeSH secundário: Adulto
Idade de Início
Feminino
Frequência do Gene
Predisposição Genética para Doença
Genótipo
Seres Humanos
Índia
Masculino
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CTLA-4 Antigen); 0 (CTLA4 protein, human); 0 (HLA-DRB1 Chains)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  6 / 13528 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29199443
[Au] Autor:Hua X; Diggelmann H; Jalukar V; Turek JW; Pagedar NA
[Ad] Endereço:1 Department of Otolaryngology-Head and Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
[Ti] Título:Successful Prediction of a Left Nonrecurrent Laryngeal Nerve in a Patient With Right-Sided Aorta and Aberrant Left Subclavian Artery.
[So] Source:Ann Otol Rhinol Laryngol;127(2):124-127, 2018 Feb.
[Is] ISSN:1943-572X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Left nonrecurrent laryngeal nerve (LNRLN) is an extremely rare anatomic variant. The development of such anatomic variation requires the regression of both the fourth (aortic arch) and sixth (ductus arteriosus, DA) arches on the left side. Preoperative prediction of this variant is difficult but might reduce risk of nerve injury. METHODS: A 34-year-old female was indicated for thyroidectomy for a 2.4 cm follicular neoplasm and Graves' disease. Due to a positive medical history of 22q11.2 microdeletion and unexplained left vocal cord paralysis, a preoperative chest computed tomography (CT) scan was obtained and revealed a right-sided aorta (RSA) and aberrant left subclavian artery (ALSA) without Kommerell's diverticulum. A left-sided NRLN was then highly suspected. RESULTS: Thyroidectomy was performed under general anesthesia with the utilization of intraoperative laryngeal nerve monitoring. A LNRLN was confirmed intraoperatively. CONCLUSIONS: Right-sided aorta and ALSA indicate embryologic regression of the left fourth primitive aortic arch. The absence of Kommerell's diverticulum at the origin of the ALSA indicates the lack of high-pressure blood flow from the pulmonary artery to the ALSA through the ductus arteriosus during embryogenesis, suggesting the embryologic regression of the left sixth primitive aortic arch. The presence of all 3 radiologic features thus highly suggests the possibility of a LNRLN.
[Mh] Termos MeSH primário: Aorta Torácica/anormalidades
Carcinoma Papilar, Variante Folicular/cirurgia
Doença de Graves/cirurgia
Nervos Laríngeos/anormalidades
Artéria Subclávia/anormalidades
Neoplasias da Glândula Tireoide/cirurgia
Tireoidectomia
[Mh] Termos MeSH secundário: Adulto
Aorta Torácica/patologia
Carcinoma Papilar, Variante Folicular/genética
Carcinoma Papilar, Variante Folicular/patologia
Síndrome de DiGeorge/genética
Síndrome de DiGeorge/patologia
Feminino
Doença de Graves/genética
Doença de Graves/patologia
Seres Humanos
Nervos Laríngeos/patologia
Artéria Subclávia/patologia
Neoplasias da Glândula Tireoide/genética
Neoplasias da Glândula Tireoide/patologia
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.1177/0003489417744318


  7 / 13528 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310374
[Au] Autor:Hu X; Zhang X; Gan H; Yu D; Sun W; Shi Z
[Ad] Endereço:Department of Endocrinology.
[Ti] Título:Horner syndrome as a postoperative complication after minimally invasive video-assisted thyroidectomy: A case report.
[So] Source:Medicine (Baltimore);96(48):e8888, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Horner syndrome is an unusual complication after thyroidectomy. PATIENT CONCERNS: We report a case of Horner syndrome in a 34-year-old female patient with Graves disease associated with papillary thyroid carcinoma who underwent left-side minimally invasive video-assisted thyroidectomy and neck dissection. DIAGNOSIS: Horner syndrome was diagnosed based on left myosis, eyelid ptosis, and mild enophthalmos, which developed in the patient on postoperative day 2. INTERVENTIONS: The patient was administered glucocorticoids and neurotrophic drugs on postoperative day 3. OUTCOME: The symptoms of Horner syndrome were significantly relieved 1 year later. LESSONS: Surgeons must be aware that Horner syndrome may be a source of iatrogenic complications, and patients also should be informed of these complications before surgery.
[Mh] Termos MeSH primário: Doença de Graves/cirurgia
Síndrome de Horner/tratamento farmacológico
Procedimentos Cirúrgicos Minimamente Invasivos
Complicações Pós-Operatórias/tratamento farmacológico
Tireoidectomia/métodos
Cirurgia Vídeoassistida
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008888


  8 / 13528 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458607
[Au] Autor:Kim HJ; Bang JI; Kim JY; Moon JH; So Y; Lee WW
[Ad] Endereço:Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea.
[Ti] Título:Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease.
[So] Source:Korean J Radiol;18(3):543-550, 2017 May-Jun.
[Is] ISSN:2005-8330
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Since Graves' disease (GD) is resistant to antithyroid drugs (ATDs), an accurate quantitative thyroid function measurement is required for the prediction of early responses to ATD. Quantitative parameters derived from the novel technology, single-photon emission computed tomography/computed tomography (SPECT/CT), were investigated for the prediction of achievement of euthyroidism after methimazole (MMI) treatment in GD. MATERIALS AND METHODS: A total of 36 GD patients (10 males, 26 females; mean age, 45.3 ± 13.8 years) were enrolled for this study, from April 2015 to January 2016. They underwent quantitative thyroid SPECT/CT 20 minutes post-injection of Tc-pertechnetate (5 mCi). Association between the time to biochemical euthyroidism after MMI treatment and %uptake, standardized uptake value (SUV), functional thyroid mass (SUVmean × thyroid volume) from the SPECT/CT, and clinical/biochemical variables, were investigated. RESULTS: GD patients had a significantly greater %uptake (6.9 ± 6.4%) than historical control euthyroid patients (n = 20, 0.8 ± 0.5%, < 0.001) from the same quantitative SPECT/CT protocol. Euthyroidism was achieved in 14 patients at 156 ± 62 days post-MMI treatment, but 22 patients had still not achieved euthyroidism by the last follow-up time-point (208 ± 80 days). In the univariate Cox regression analysis, the initial MMI dose ( = 0.014), %uptake ( = 0.015), and functional thyroid mass ( = 0.016) were significant predictors of euthyroidism in response to MMI treatment. However, only %uptake remained significant in a multivariate Cox regression analysis ( = 0.034). A %uptake cutoff of 5.0% dichotomized the faster responding versus the slower responding GD patients ( = 0.006). CONCLUSION: A novel parameter of thyroid %uptake from quantitative SPECT/CT is a predictive indicator of an early response to MMI in GD patients.
[Mh] Termos MeSH primário: Doença de Graves/diagnóstico por imagem
Tomografia Computadorizada de Emissão de Fóton Único
[Mh] Termos MeSH secundário: Adulto
Antitireóideos/uso terapêutico
Feminino
Doença de Graves/tratamento farmacológico
Doença de Graves/patologia
Seres Humanos
Masculino
Metimazol/uso terapêutico
Meia-Idade
Modelos de Riscos Proporcionais
Pertecnetato Tc 99m de Sódio/química
Tireotropina/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antithyroid Agents); 554Z48XN5E (Methimazole); 9002-71-5 (Thyrotropin); A0730CX801 (Sodium Pertechnetate Tc 99m)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.3348/kjr.2017.18.3.543


  9 / 13528 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743746
[Au] Autor:Citterio CE; Veluswamy B; Morgan SJ; Galton VA; Banga JP; Atkins S; Morishita Y; Neumann S; Latif R; Gershengorn MC; Smith TJ; Arvan P
[Ad] Endereço:From the Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan 48105.
[Ti] Título: triiodothyronine formation from thyrocytes activated by thyroid-stimulating hormone.
[So] Source:J Biol Chem;292(37):15434-15444, 2017 09 15.
[Is] ISSN:1083-351X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The thyroid gland secretes primarily tetraiodothyronine (T ), and some triiodothyronine (T ). Under normal physiological circumstances, only one-fifth of circulating T is directly released by the thyroid, but in states of hyperactivation of thyroid-stimulating hormone receptors (TSHRs), patients develop a syndrome of relative T toxicosis. Thyroidal T production results from iodination of thyroglobulin (TG) at residues Tyr and Tyr , whereas thyroidal T production may originate in several different ways. In this study, the data demonstrate that within the carboxyl-terminal portion of mouse TG, T is formed independently of deiodination from T We found that upon iodination , T formation in TG was decreased in mice lacking TSHRs. Conversely, T that can be formed upon iodination of TG secreted from PCCL3 (rat thyrocyte) cells was augmented from cells previously exposed to increased TSH, a TSHR agonist, a cAMP analog, or a TSHR-stimulating antibody. We present data suggesting that TSH-stimulated TG phosphorylation contributes to enhanced T formation. These effects were reversed within a few days after removal of the hyperstimulating conditions. Indeed, direct exposure of PCCL3 cells to human serum from two patients with Graves' disease, but not control sera, led to secretion of TG with an increased intrinsic ability to form T upon iodination. Furthermore, TG secreted from human thyrocyte cultures hyperstimulated with TSH also showed an increased intrinsic ability to form T Our data support the hypothesis that TG processing in the secretory pathway of TSHR-hyperstimulated thyrocytes alters the structure of the iodination substrate in a way that enhances T formation, contributing to the relative T toxicosis of Graves' disease.
[Mh] Termos MeSH primário: Processamento de Proteína Pós-Traducional
Receptores da Tireotropina/agonistas
Transdução de Sinais
Tireoglobulina/metabolismo
Células Epiteliais da Tireóide/metabolismo
Tireotropina/metabolismo
Tri-Iodotironina/biossíntese
[Mh] Termos MeSH secundário: Animais
Proteínas de Ligação ao Cálcio/agonistas
Proteínas de Ligação ao Cálcio/genética
Proteínas de Ligação ao Cálcio/metabolismo
Caseína Quinase I/genética
Caseína Quinase I/metabolismo
Linhagem Celular
Células Cultivadas
Proteínas da Matriz Extracelular/agonistas
Proteínas da Matriz Extracelular/genética
Proteínas da Matriz Extracelular/metabolismo
Doença de Graves/sangue
Doença de Graves/metabolismo
Doença de Graves/patologia
Halogenação
Seres Humanos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Fosforilação
Proteínas Serina-Treonina Quinases/química
Proteínas Serina-Treonina Quinases/genética
Proteínas Serina-Treonina Quinases/metabolismo
Ratos
Receptores da Tireotropina/genética
Receptores da Tireotropina/metabolismo
Tireoglobulina/secreção
Células Epiteliais da Tireóide/citologia
Células Epiteliais da Tireóide/patologia
Células Epiteliais da Tireóide/secreção
Tirosina/metabolismo
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Calcium-Binding Proteins); 0 (Extracellular Matrix Proteins); 0 (FAM20C protein, mouse); 0 (Receptors, Thyrotropin); 06LU7C9H1V (Triiodothyronine); 42HK56048U (Tyrosine); 9002-71-5 (Thyrotropin); 9010-34-8 (Thyroglobulin); EC 2.7.11.1 (Casein Kinase I); EC 2.7.11.1 (FAM20C protein, human); EC 2.7.11.1 (Fam20C protein, rat); EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171230
[Lr] Data última revisão:
171230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1074/jbc.M117.784447


  10 / 13528 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29180171
[Au] Autor:Lin YS; Lin JD; Hsu CC; Yu MC
[Ad] Endereço:Department of Surgery, Chang Gung Memorial Hospital Linkou Branch, Chang Gung University, Taoyuan City, Taiwan (R.O.C.).
[Ti] Título:The long-term outcomes of thyroid function after subtotal thyroidectomy for Graves' hyperthyroidism.
[So] Source:J Surg Res;220:112-118, 2017 Dec.
[Is] ISSN:1095-8673
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Surgical management of Graves' disease (GD) is changing from subtotal to total thyroidectomy because the latter eliminates the risk of recurrence. However, to preserve thyroid function in a euthyroid state, subtotal thyroidectomy is still performed for GD in non-Western countries. Therefore, we designed a study to investigate the long-term outcomes in GD patients after subtotal thyroidectomy and the correlation between remnant weight and postoperative thyroid function. MATERIALS AND METHODS: This was a retrospective cohort observation study. Between January 2005 and December 2011, 415 consecutive GD patients treated by subtotal thyroidectomy were enrolled. All data were collected from 385 patients who underwent bilateral subtotal thyroidectomy and 57 patients who underwent the Hartley-Dunhill operation. The median postoperative follow-up time was 72 months (range 12-144 months). RESULTS: The mean weight of the preserved thyroid remnant was 5.1 g. Persistent or recurrent hyperthyroidism was observed in 119 (28.7%) patients. The median time of recurrence was 36 months (range 12-120 months). Hypothyroidism developed in over 50% of patients. A euthyroid state was achieved in only 19.3% of patients, and the rate did not increase significantly as remnant weight increased. Based on a Cox regression analysis, the remnant weight is an independent risk factor for persistent or recurrent hyperthyroidism (hazard ratio: 1.323, 95% confidence interval: 1.198-1.461, P < 0.001). CONCLUSIONS: Subtotal thyroidectomy with the intent to maintain a euthyroid state is not an optimal surgical strategy for the definitive treatment of GD because the persistence or recurrence rate is high and the euthyroid rate is lower than expected.
[Mh] Termos MeSH primário: Doença de Graves/cirurgia
Hipotireoidismo/epidemiologia
Complicações Pós-Operatórias/epidemiologia
Glândula Tireoide/fisiologia
Tireoidectomia/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Feminino
Seguimentos
Seres Humanos
Hipotireoidismo/etiologia
Masculino
Meia-Idade
Complicações Pós-Operatórias/etiologia
Período Pós-Operatório
Recidiva
Estudos Retrospectivos
Fatores de Risco
Tireoidectomia/métodos
Fatores de Tempo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE



página 1 de 1353 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde